Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A panel of experts advising the US Food and Drug Administration voted Thursday against approving for sale a new obesity treatment called Qnexa, citing safety risks.
The FDA is not required to follow the recommendation of the expert panel on endocrinological and metabolic drugs, but generally accepts its findings.
Qnexa, made by California-based biotech firm Vivus, is the first obesity drug submitted to the FDA in a decade.
While a high percentage of Americans are overweight or obese, there are few medical treatments, and those on the market can have side effects including increased heart problems and intestinal gas.
Leland Wilson, chief executive officer at Vivus, said the company was still optimistic it would win final approval for Qnexa.
"We are disappointed with the advisory committee's vote," he said in a statement.
"While the final vote was close, and we are encouraged that the committee recognized the efficacy demonstrated in the Qnexa clinical trials, we will work closely with the FDA leading up to our October 28, 2010 (decision) date to address the labeling and safety questions raised during today's proceedings. We remain committed to patients living with obesity and weight-related disease."
Qnexa combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can be used in conjunction with other drugs for weight loss.
js-rl/jkb
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments